A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 8009-8009 ◽  
Author(s):  
David R. Spigel ◽  
Karen L. Reckamp ◽  
Naiyer A. Rizvi ◽  
Elena Poddubskaya ◽  
Howard Jack West ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Programmed Death ◽  
Phase Iii Study ◽  
Programmed Death 1 ◽  
Previously Treated

scholarly journals Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer

2018 ◽  
Vol 29 (7) ◽  
pp. 1548-1553 ◽  
Author(s):  
D.E. Gerber ◽  
L. Horn ◽  
M. Boyer ◽  
R. Sanborn ◽  
R. Natale ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Phase Iii Study ◽  
Previously Treated

PL-5 A phase III study of pemetrexed vs. docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) who were previously treated with chemotherapy

Lung Cancer ◽  
2003 ◽  
Vol 41 ◽  
pp. S4 ◽  
Author(s):  
Frances A. Shepherd ◽  
Jose R. Pereira ◽  
Joachim Von Pawel ◽  
Ulrich Gatzemeier ◽  
Thomas Chang Yao Tsao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Phase Iii Study ◽  
Previously Treated
Sign in / Sign up

Export Citation Format

Share Document